A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
NCT06457919
This study is recruiting at 11 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant prostate cancer (mCRPC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Last updated on ClinicalTrials.gov
- June 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Yale University (Data Collection Only) · New Haven, CT
New Jersey · 3
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, NJ
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, NJ
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, NJ
New York · 5
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) · Commack, NY
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, NY
- Columbia University · New York, NY
- Memorial Sloan Kettering Cancer Center · New York, NY
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) · Uniondale, NY
North Carolina · 1
- Duke University · Durham, NC
Oregon · 1
- Oregon Health & Science University · Portland, OR
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.